^
Association details:
| Biomarker: | HRAS A146T |
|---|---|
| Cancer: | Squamous Cell Carcinoma of Head and Neck |
| Drug: | Zarnestra (tipifarnib) (CXCL12 inhibitor, Farnesyl transferase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Tipifarnib as a Precision Therapy for HRAS-Mutant Head and Neck Squamous Cell Carcinomas
Excerpt:
...the expansion of the study to include PDX models increased the range of hotspot mutations to include A146T (HN1420 model), G12S (HN2579), G13R (HN2581), and K117N (HN3504; Fig. 1D)...tipifarnib displayed selective antitumor activity in HRAS-mutant HNSCC PDX models.
DOI:
10.1158/1535-7163.MCT-19-0958
